Guess which ASX healthcare share is booming 28% on a sales boost

Investors are bidding up the ASX healthcare share after the company reported it's on track to substantially exceed product sales reported in FY22.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) is up 0.2% today, but this little-known ASX healthcare share is leaving those gains in the dust.

Any guesses?

If you said medical technology stock Next Science Ltd (ASX: NXS) go to the front of the class.

The ASX healthcare share closed yesterday trading for 48 cents. Next Science shares were fetching 61.5 cents in earlier trade, up more than 28%. At the time of writing, shares are swapping hands for 58 cents, for an intraday gain of 21%.

Here's what's piquing investor interest today.

Man pointing at a blue rising share price graph.

Image source: Getty Images

What did the ASX healthcare share report?

The Next Science share price is rocketing after the company reported "continuing improvement" in its business performance in the current quarter.

With just two days left in June, the ASX healthcare share said it expects unaudited product sales for 2QFY23 to come in above US$5.6 million (AU$8.5 million). That's up from reported product sales of US$4.4 million in the prior quarter.

Next Science reported that with the second quarter almost concluded, the company is clearly on track to "substantially exceed product sales" of US$5.2 million reported in 1HFY22 as well as the US$6.1 million reported in 2HFY22.

Management of the ASX healthcare share attributed the strong performance to increased investments in sales and marketing. They added that this "will continue during the establishment phase of our direct sales model for key products".

Among the quarter's highlights, monthly sales in Next Science's Wound Care DME business exceeded $1 million in April.

Likely helping stir investor enthusiasm, the company noted, "Operating momentum has continued through the current quarter with ongoing evidence of sales traction in the commercial wound care market."

Next Science share price snapshot

Despite today's big intraday boost, the ASX healthcare share remains down 11% in 2023.

Next Science is focused on commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections on human health.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Next Science. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air
Healthcare Shares

Healthcare shares led the ASX 200 last week. Is a sector comeback underway?

ASX 200 healthcare shares are down 39% over 12 months, but have lifted 13% since 3 June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

If I invest $8,000 in CSL shares, how much passive income will I receive in 2027?

This business could deliver healthy payouts in the next few years…

Read more »

Surgeon looking at a monitor in an operating room.
Healthcare Shares

The bull and bear case for CSL shares

What are the realistic prospects for this once powerful healthcare company?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this red-hot ASX healthcare share keeps climbing

A 1,600% gain hasn't slowed this stock down.

Read more »

A woman smiles at the outlook she sees through binoculars.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can this business deliver very healthy gains from here?

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Why is this ASX biotech stock blasting higher today?

Investors are backing the biotech's growing commercial and pipeline potential.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

Down 30%, should I buy ResMed shares now?

A sharp fall can make investors cautious, but it can also create opportunity when the long-term business remains strong.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 beaten-down ASX healthcare shares tipped to rise up to 202%

Analysts have a strong buy rating on two of these healthcare stocks, and all three are tipped to have an…

Read more »